[Lani]

Median follow-up from the time of diagnosis of MBC was 3.2 years (range 0.1–16.3 years). Median OS from the time of MBC diagnosis was 3.9 years (95 % CI 3.4–5.2 years; Fig. 1a). Notably, 56 (33 %) and 12 (7 %) patients were alive ≥5 years and ≥10 or more years, respectively, after diagnosis of MBC. Median PFS from the time of diagnosis of MBC to initiation of second-line therapy was 1.3 years (95 % CI 1.1–1.6; Fig. 1b). Of the 96 patients with biopsy-proven distant metastases, 5 (5 %) were free of detectable active disease by routine imaging at ≥10 years. There was no difference in survival between those with and without biopsy confirmation of metastatic disease (HR 0.88 [95 % CI 0.6–1.3], P = 0.49). For the 39 % of patients who were diagnosed with CNS metastases at any time during their disease course, median survival from the time of diagnosis of CNS metastasis was 1.5 years (95 % CI 1.1–2.6).